RP-HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-20. Numbers and descriptions here follow the published literature rather than marketing material.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
== Effect on investment, sales and profit == According to Thomson Reuters in their 2012 publication "The Economic Power of Orphan Drugs", there has been increased investment in orphan drug research and development, partly due to the U.S. Orphan Drug Act of 1983 (ODA) and similar acts in other regions of the world driven by "high-profile philanthropic funding". According to a 2012 article in Drug Discovery Today, the years 2001 to 2011 were the "most productive period in the history of orphan drug development, in terms of average annual orphan drug designations and orphan drug approvals". For the same decade the compound annual growth rate (CAGR) of the orphan drugs was an "impressive 25.8%, compared to only 20.1% for a matched control group of non-orphan drugs". By 2012, the market for orphan drugs was worth US$637 million, compared with US$638 million for a control group of non-orphan drugs. By 2012,
Metabolically label O-GlcNAc to install O-GlcNAz onto proteins Use click chemistry to link IsoTaG probe to O-GlcNAz Use streptavidin beads to enrich for tagged proteins Treat beads with trypsin to release non-modified peptides Cleave isotopically recoded glycopeptides from beads using mild acid Obtain a full-scan mass spectrum from isotopically recoded glycopeptides Apply algorithm to detect unique isotope signature from probe Perform tandem MS on the isotopically recoded species to obtain glycopeptide amino acid sequences Search protein database for identified sequences Other methodologies have been developed for quantitative profiling of O-GlcNAc using differential isotopic labeling. Example probes generally consist of a biotin affinity tag, a cleavable linker (acid- or photo-cleavable), a heavy or light isotopic tag, and an alkyne. O-GlcNAc modification has also been recently reported on tyrosine residues, though these represent roughly 5% of all O-GlcNAc modifications.
==== Elimination ==== Pregabalin is eliminated by the kidneys in the urine, mainly in its unchanged form. It has a relatively short elimination half-life, with a reported value of 6.3 hours. Because of its short elimination half-life, pregabalin is administered 2 to 3 times per day to maintain therapeutic levels. The kidney clearance of pregabalin is 73 mL/minute. As pregabalin clearance is directly proportional to creatinine clearance, renal impairment leads to drug accumulation and elevated plasma concentrations. Dose adjustment is therefore required in patients with a creatinine clearance below 60 mL/min, with progressively greater reductions recommended as renal function declines. Patients undergoing hemodialysis require supplemental dosing following each session, as a standard four-hour treatment reduces plasma pregabalin concentrations by approximately 50%.
In September 2022, the WHO updated their guidelines to recommend use of remdesivir for both non-hospitalized and hospitalized patients. This was based on final results from the SOLIDARITY trial that showed a reduction in mortality or progression to mechanical ventilation for non-ventilated patients.
The industry is predominantly composed of small and medium-sized enterprises (SMEs) and is heavily concentrated geographically, with 75% of registered AI company offices located in London, the South East, and the East of England. Investment in dedicated UK AI companies reached a record £2.9 billion in 2024, driven largely by international investors. However, the sector faces a persistent "scale-up gap" for companies seeking growth capital beyond the Series A stage, as well as a critical skills shortage, particularly in technical roles and understanding AI concepts. The National AI Strategy (2021) laid out a ten-year plan to invest in the AI ecosystem, support adoption, and establish a governance framework. In 2023, the UK hosted the inaugural global AI Safety Summit, leading to the Bletchley Declaration and the establishment of the AI Security Institute (AISI) to evaluate frontier AI models. The 2025 AI Opportunities Action Plan set strategic goals to secure computing infrastructure, drive public sector adoption, and build domestic AI capabilities, supported by a £2 billion investment in AI infrastructure and the creation of "AI Growth Zones". In contrast to the European Union's comprehensive AI Act, the UK has adopted a "pro-innovation", sector-specific regulatory approach. Rather than creating a single AI regulator, the UK relies on existing bodies (such as the Competition and Markets Authority, Information Commissioner, and Financial Conduct Authority) to apply cross-cutting principles to AI systems within their domains.
Sources: en.wikipedia.org
Most cases have been diagnosed post-mortem following a biopsy of the patient's brain tissue. It takes one to twelve days, median five, for symptoms to appear after nasal exposure to N. fowleri flagellates. Symptoms may include headache, fever, nausea, vomiting, loss of appetite, altered mental state, coma, drooping eyelid, blurred vision, and loss of the sense of taste. Later symptoms may include stiff neck, confusion, lack of attention, loss of balance, seizures, and hallucinations. Once symptoms begin to appear, the patient usually dies within two weeks. N. fowleri is not contagious; an infected person cannot transmit the infection. Primary amoebic meningoencephalitis is classified as a rare disease in the United States, as it affects fewer than 200,000 people. From 2013 to 2022, 29 infections were reported in the US, which compares with about 4,000 annual deaths by drowning. It is so rare that individual cases are often reported internationally, with 381 cases reported globally. The true number of cases is likely to be higher than those reported due to problems related with diagnosis, access to diagnostic testing and a lack of surveillance. Over 40% of all known global cases of primary amoebic meningoencephalitis are reported in the United States. Animals can become infected by Naegleria fowleri. This is rarely observed, although many cases are thought to be overlooked. Experimentally, mice, guinea pigs, and sheep have been infected, and there have been reports of South American tapirs and cattle contracting PAM.
Some microorganisms alter net surface charges. Staphylococcus aureus transports D-alanine from the cytoplasm to the surface teichoic acid which reduces the net negative charge by introducing basic amino groups. S. aureus also modifies its anionic membranes via MprF with L-lysine, increasing the positive net charge. The interaction of antimicrobial peptides with membrane targets can be limited by capsule polysaccharide of Klebsiella pneumoniae. Salmonella species reduce the fluidity of their outer membrane by increasing hydrophobic interactions between an increased number of Lipid A acyl tails by adding myristate to Lipid A with 2-hydroxymyristate and forming hepta-acylated Lipid A by adding palmitate. The increased hydrophobic moment is thought to retard or abolish antimicrobial peptide insertion and pore formation. The residues undergo alteration in membrane proteins. In some Gram-negative bacteria, alteration in the production of outer membrane proteins correlates with resistance to killing by antimicrobial peptides. Non-typeable Hemophilus influenzae transports AMPs into the interior of the cell, where they are degraded. Furthermore, H. influenzae remodels its membranes to make it appear as if the bacterium has already been successfully attacked by AMPs, protecting it from being attacked by more AMPs. ATP-binding cassette transporters import antimicrobial peptides and the resistance-nodulation cell-division efflux pump exports antimicrobial peptides.
Most proteins consist of linear polymers built from series of up to 20 L-α-amino acids. All proteinogenic amino acids have a common structure where an α-carbon is bonded to an amino group, a carboxyl group, and a variable side chain. Only proline differs from this basic structure as its side chain is cyclical, bonding to the amino group, limiting protein chain flexibility. The side chains of the standard amino acids have a variety of chemical structures and properties, and it is the combined effect of all amino acids that determines its three-dimensional structure and chemical reactivity. The amino acids in a polypeptide chain are linked by peptide bonds between amino and carboxyl group. An individual amino acid in a chain is called a residue, and the linked series of carbon, nitrogen, and oxygen atoms are known as the main chain or protein backbone. The peptide bond has two resonance forms that confer some double-bond character to the backbone. The alpha carbons are roughly coplanar with the nitrogen and the carbonyl (C=O) group. The other two dihedral angles in the peptide bond determine the local shape assumed by the protein backbone. One consequence of the N-C(O) double bond character is that proteins are somewhat rigid. A polypeptide chain ends with a free amino group, known as the N-terminus or amino terminus, and a free carboxyl group, known as the C-terminus or carboxy terminus. By convention, peptide sequences are written N-terminus to C-terminus, correlating with the order in which proteins are synthesized by ribosomes.
== Nomenclature == The term "penicillin" is defined as the natural product of Penicillium mould with antimicrobial activity. It was coined by Alexander Fleming on 7 March 1929 when he discovered the antibacterial property of Penicillium rubens. Fleming explained in his 1929 paper in the British Journal of Experimental Pathology that "to avoid the repetition of the rather cumbersome phrase 'Mould broth filtrate', the name 'penicillin' will be used". The name thus refers to the scientific name of the mould, as described by Fleming in his Nobel lecture in 1945:
Sources: en.wikipedia.org
Simon Khung, a social media influencer who eventually stopped taking drugs after the 2020 murder of his daughter Megan Khung (who was allegedly killed by her mother), told a newspaper in 2024 that he supported the death penalty for drug trafficking, as he felt that the drug situation in Singapore would grow worse in the absence of capital punishment and more people would become drug abusers and ruin their lives like he and the former abusers had in their pasts; Khung's stance was supported by other ex-abusers, and one of them, Bruce Mathieu (who overcame his drug addiction seven years prior), said that the death penalty had deterred him from resorting to drug smuggling. In the aftermath of several executions, there were discussions among the Singaporean public about the need for compassion for some death row inmates, owing to arguments that many death row inmates had come from low-income families or had drug addictions before ending up on death row. However, the public sentiments remained leaning towards capital punishment for drugs, owing to arguments concerning rampant rates of drug trafficking in the Golden Triangle in Southeast Asia, the effectiveness of the death penalty in maintaining Singapore's low crime rate, and the impact drugs have had on the addicts and their families. When 31-year-old Singaporean Shen Hanjie was sentenced to death for trafficking 34.94g of pure heroin in October 2022, a huge majority of the netizens showed support for the death sentence in Shen's case, with some expressing sympathy for his family, especially his parents.
The blood clot is only a temporary solution to stop bleeding; tissue repair is needed. Small interruptions in the endothelium are handled by physiological mechanisms; large interruptions by a trauma surgeon. The fibrin is slowly dissolved by the fibrinolytic enzyme, plasmin, and the platelets are cleared by phagocytosis. Platelets release platelet-derived growth factor (PDGF), a potent chemotactic agent; and TGF beta, which stimulates the deposition of extracellular matrix; fibroblast growth factor, insulin-like growth factor 1, platelet-derived epidermal growth factor, and vascular endothelial growth factor. Local application of these factors in increased concentrations through platelet-rich plasma (PRP) is used as an adjunct in wound healing.
=== Choosing a support === Compatibility of support fabrics is crucial when selecting a support material. Because textiles vary so greatly careful research is necessary when making these choices. There are alternative options to fabric supports that are also important to consider. Composition, processing, structure, rigidity, and weight are all factors to consider when determining the appropriateness of a paper-based or non-textile material as a support for stabilization. The physical and chemical compatibility of textiles and long-term stability should also be evaluated for materials that will be stored in close proximity to textile artifacts.
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.